KIR3DL2 and renal cell carcinoma: Besides PD-1/PD-L1, more immune checkpoint or cell death related molecules (i.e., indoleamine 2, 3-dioxygenase, killer cell immunoglobulin-like receptor, lymphocyte-activation gene 3) will be discovered or revealed [122], and the combination of targeted therapy direct to the cancer stem cells with the immune checkpoint or cell death related molecules will also be promising for overcoming the multiresistance in RCC targeted therapy.